Target intelligence / Profile preview

Mas-related G-protein coupled receptor member X3 (MRGPRX3)

Target
MRGPRX3
Molecular classification
G protein-coupled receptor, Receptor, Rhodopsin-like class A GPCR
01

Overview

Mas-related G-protein coupled receptor member X3 (MRGPRX3) is a primate-specific orphan receptor in the delta branch of the rhodopsin-like class A GPCR family. It is predominantly expressed in sensory neurons as well as some immune cells and is part of a subfamily that includes MRGPRX1, -2, -3, and -4. MRGPRX3 is structurally unique compared to canonical GPCRs, with key differences in its ligand binding pocket and lack of certain conserved motifs. While its closest homologs, especially MRGPRX1 and MRGPRX2, have well-studied roles in mediating pain, itch, neuroinflammation, mast cell responses, and pseudoallergic reactions, the specific functions of MRGPRX3 are less well elucidated. The MRGPRX family receives diverse small molecule and peptide ligands and is of high interest as a non-opioid therapeutic target for pain and related conditions, although no selective clinical drugs or biomarkers for MRGPRX3 have yet been established.

Other names
Mas-related GPR family member X3MRGX3SNSR1SNSR2Sensory neuron-specific G-protein coupled receptor 1Sensory neuron-specific G-protein coupled receptor 2G protein-coupled receptor MRGX3G protein-coupled receptor SNSR1G protein-coupled receptor SNSR2mas-related GPCR member X3
02

Mechanism of action

Drugs targeting MRGPRX family generally act as agonists or antagonists at the receptor, modulating pain, itch, or immune signaling via G protein-coupling and downstream effectors. Mechanisms for MRGPRX3 itself are likely similar, but specific drug-receptor interactions have not been delineated.

03

Biological functions

Signal transductionSensory perception (pain, itch)NeurotransmissionImmune response (expression on sensory neurons and immune cells)
04

Disease associations

Pain (nociception, chronic pain)Itch (pruritus)InflammationNeuroinflammatory conditionsWound healing (potential)Possibly cancer (potential, not confirmed)
05

Safety considerations

Lack of specific safety data as no drugs are approved for this targetGiven MRGPRs' role in sensory neuron signaling and immune response, theoretical risks include altered pain perception, dysregulated itch, or impairment in immune/neuroimmune homeostasis if therapeutically modulated
06

Interacting drugs

No well-characterized approved drugs or clinically used compounds specifically targeting MRGPRX3

1 more in the full profile.

07

Biomarkers

No well-validated clinical biomarkers specific for MRGPRX3 patient selection or efficacy monitoring currently reported

Beyond the preview

Go deeper on Mas-related G-protein coupled receptor member X3 (MRGPRX3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mas-related G-protein coupled receptor member X3 (MRGPRX3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call